| Vol. 11.46 – 24 November, 2020 |
| |
|
|
| Researchers demonstrated that supt16h, a component of the Facilitates chromatin transcription complex, was required for hematopoietic stem and progenitor cell formation. [Nature Cell Biology] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Using a murine model of malaria and combining single-cell RNA sequencing, mathematical modeling, transplantation assays and intravital microscopy, scientists showed that hematopoiesis was reprogrammed upon infection, whereby the HSC compartment turned over substantially faster than at steady-state and HSC function was drastically affected. [Nature Cell Biology] |
|
|
|
| Fast-cycling stem-like leukemia cells demonstrated Notch activation and were effectively eliminated in patients by Notch inhibition, while slow cycling stem-like cells were Notch-independent but rather relied on PI3K signaling, likely explaining the poor efficacy of Notch inhibition in this disease. [Blood] |
|
|
|
| Scientists demonstrated that mice with RANKL deficiency in MALPs have a drastic increase in trabecular bone mass in long bones and vertebrae starting from one month of age, while their cortical bone appears normal. [Journal of Clinical Investigation] |
|
|
|
| Investigators identified nonlinear changes in age-related microRNAs by analyzing whole blood from 1334 healthy individuals. They observed a larger influence of the age as compared to the sex and provide evidence for a shift to the 5’ mature form of miRNAs in healthy aging. [Nature Communications] |
|
|
|
| Researchers tested the efficacy and pharmacodynamic activity of an oligonucleotide inhibitor of miR-155, cobomarsen, in non-Germinal Center B-cell or activated B-cell subtype of Diffuse Large B-cell Lymphoma cell lines and in corresponding xenograft mouse models. [Clinical Cancer Research] |
|
|
|
| An unbiased RNA-seq approach was developed to interrogate DAC-induced transcriptome changes in AML cell lines with or without a deletion of chromosomes 7q, 5q or 17p. Hypomethylating agent treatment preferentially upregulated several hemizygous tumor suppressor genes in this genomic region, significantly derepressing endogenous retrovirus 3-1 with promoter demethylation, enhanced chromatin accessibility, and increased H3K4me3 levels. [Cancer Research] |
|
|
|
| The authors report that dihydropyrimidinase like 2 (DPYSL2), also known as CRMP2, was a novel key differentiation mediator downstream of Krüppel-like factor 4 (KLF4) in acute myeloid leukemia cells. [Scientific Reports] |
|
|
|
| Researchers studied Dengue virus infection of MEG-01 cells to understand its effect on megakaryopoiesis and the generation of platelet-like-particles. [Scientific Reports] |
| |
|
|
| Investigators prospectively measured insulin-like growth factor-l (IGF-l) concentrations in 121 pediatric patients before, during, and after allogeneic hematopoietic stem cell transplantation. Overall, IGF-l levels were significantly reduced compared with healthy sex- and age-matched children. [Bone Marrow Transplantation] |
|
|
|
| Scientists tested the use of low-dose memory donor lymphocyte infusion after engraftment of αβ T cell-depleted grafts. A cohort of 131 pediatric patients were grafted with αβ T cell-depleted products from either haplo or unrelated donors. [Bone Marrow Transplantation] |
|
|
|
|
| The authors evaluate evidence for a layered hematopoietic system across species. They discuss mechanisms and selective pressures leading to the temporal generation of different cell types. [Frontiers in Cell and Developmental Biology] |
|
|
|
|
| Orchard Therapeutics announced that the FDA has cleared the company’s Investigational New Drug application for OTL-200, an autologous, hematopoietic stem cell, lentiviral vector-based gene therapy in development for the treatment of MLD. [Orchard Therapeutics] |
|
|
|
| BeiGene, Ltd. announced that the China National Medical Products Administration has approved XGEVA® for the prevention of skeletal-related events in patients with bone metastases from solid tumors and in patients with multiple myeloma. [BeiGene, Ltd.] |
|
|
|
|
| September 7 – September 11, 2022 Woods Hole, Massachusetts, United States |
|
|
|
|
|
| Rubius Therapeutics – Cambridge, Massachusetts, United States |
|
|
|
| St. Jude Children’s Research Hospital – Memphis, Tennessee, United States |
|
|
|
| Stanford University – Stanford, California, United States |
|
|
|
| New York Blood Center – New York, New York, United States |
|
|
|
| The University of British Columbia – Vancouver, British Columbia, Canada |
|
|
|
|